ArticleInfection and drug resistance2019
Increase in antibiotic resistant
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Third-Line and Later Susceptibility-GuidedJournal of clinical medicine · 2026Article
- Evidence of Helicobacter pylori heterogeneity in human stomachs by susceptibility testing and characterization of mutations in drug-resistant isolates.Scientific reports · 2024Article
- Role of MIC levels and 23S rRNA mutation sites to clarithromycin in 14-day clarithromycin bismuth quadruple therapy forHeliyon · 2024Article
- Analysis of Helicobacter pylori resistance in patients with different gastric diseases.Scientific reports · 2024Article
- The Prevalence, Risk Factors, and Antimicrobial Resistance Determinants ofInfectious disease reports · 2024Article
- Quantitative multiplex real-time polymerase chain reaction assay for the detection of Helicobacter pylori and clarithromycin resistance.BMC microbiology · 2023Article
- Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.Journal of clinical laboratory analysis · 2023Review
- Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing.Helicobacter · 2022Article
- Overview ofGut and liver · 2021Review
- Correlation Analysis Among Genotype Resistance, Phenotype Resistance and Eradication Effect ofInfection and drug resistance · 2021Article
- Metronidazole-resistantNew microbes and new infections · 2020Article
- Trends inMicrobial genomics · 2020Review
- E-test versus agar dilution for antibiotic susceptibility testing of Helicobacter pylori: a comparison study.BMC research notes · 2020Article
- Genotype profiles ofTherapeutic advances in gastroenterology · 2020Article
- Phenotypic and Genotypic Antibiotic Resistance Patterns inFrontiers in cellular and infection microbiology · 2020Article
- A Next-Generation Sequencing-Based Approach to Identify Genetic Determinants of Antibiotic Resistance in CambodianJournal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEradication effectively prevents MATERIALS AND
methods
resultsRates of amoxicillin, clarithromycin, and metronidazole resistance were 13%, 48%, and 49%, respectively. Genetic analysis indicated that the A2143G point mutation in 23S rDNA is closely associated with the MIC of clarithromycin. The MIC in amoxicillin-resistant strains increased with an increase in the number of PBP1A amino acids mutations.
conclusionGenetic analysis for resistant strains is not clinically effective in cases of amoxicillin resistance. Numerous bacteria with already high antibiotic resistance rates have been isolated in large hospitals such as a University Hospital. For effective eradication therapy, MIC measurement should be considered via several methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.